Peter H. O'Donnell to Incidence
This is a "connection" page, showing publications Peter H. O'Donnell has written about Incidence.
Connection Strength
0.066
-
Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease. Leuk Lymphoma. 2010 Dec; 51(12):2240-9.
Score: 0.066